Research Analysts Set Expectations for YMAB FY2024 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Equities research analysts at Brookline Capital Management issued their FY2024 earnings per share estimates for shares of Y-mAbs Therapeutics in a report issued on Wednesday, December 4th. Brookline Capital Management analyst K. Dolliver expects that the company will post earnings of ($0.75) per share for the year. Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.66) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($0.94) EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same quarter in the previous year, the firm earned ($0.18) EPS.

A number of other research firms have also recently issued reports on YMAB. Canaccord Genuity Group restated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a report on Friday, November 15th. Wedbush reiterated an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. BMO Capital Markets lowered their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Finally, Morgan Stanley lowered their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Stock Up 0.2 %

YMAB opened at $10.28 on Monday. The business has a fifty day moving average of $13.12 and a 200 day moving average of $12.73. Y-mAbs Therapeutics has a 52-week low of $6.09 and a 52-week high of $20.90. The stock has a market cap of $460.44 million, a P/E ratio of -19.04 and a beta of 0.61.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at $877,822.57. This represents a 30.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in YMAB. Price T Rowe Associates Inc. MD increased its position in Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock valued at $345,000 after buying an additional 1,657 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Y-mAbs Therapeutics by 8.0% in the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after purchasing an additional 8,974 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in shares of Y-mAbs Therapeutics by 4.2% in the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after purchasing an additional 3,589 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Y-mAbs Therapeutics by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock worth $993,000 after purchasing an additional 2,760 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.